Lupuzor Phase 3 results Peptide P140, a synthetic peptide derived from the spliceosomal protein U1-70K, has emerged as a promising immunomodulatory agent, particularly for the treatment of autoimmune diseases like systemic lupus erythematosus (SLE)Physicochemical properties of P140 peptide. (a) .... This phosphopeptide, phosphorylated at the Ser140 position, functions by targeting and depleting hyper-activated autoreactive T and B cells, thereby restoring immune homeostasis. Its unique mechanism of action, which involves binding to the HSC70 chaperone protein and transiently abolishing T cell reactivity, sets it apart from conventional therapeutic approaches.
The therapeutic efficacy of peptide P140 stems from its ability to selectively interact with specific components of the immune system. Research indicates that P140 binds to the HSPA8/HSC70 chaperone protein, which is often overexpressed in conditions like lupus. This binding event leads to a reduction in the functional expression of HSC70, a critical factor in the survival and activation of autoreactive immune cells.
Furthermore, peptide P140 has been shown to increase apoptosis in peripheral blood lymphocytes of lupus-prone mice and decrease autoepitope recognition by T cellsP140is a syntheticpeptideissued from the U1-70K protein. It was chemically modified and contains a phosphoserine residue at position 140.. This dual action – promoting the elimination of aberrant immune cells and reducing their ability to target self-antigens – contributes to its overall immunomodulatory effectResetting the autoreactive immune system with a .... The peptide's ability to act as an altered peptide ligand for the T cell receptor is also thought to play a role in restoring tolerance.
The potential of peptide P140 as an immunomodulator has been explored in various studies, with a significant focus on its application in systemic lupus erythematosus (SLE). Clinical trials, including a randomized, double-blind, placebo-controlled Phase IIb trial, have investigated the safety, tolerability, and efficacy of P140 (also known by its investigational drug name Lupuzor or forigerimod).P140 Peptide Leads to Clearance of Autoreactive ... These trials have suggested that a longer treatment period may be necessary to observe a greater number of responders, indicating a potential for sustained therapeutic benefit.
Beyond SLE, preliminary research has also explored the therapeutic effects of peptide P140 in other inflammatory conditions, such as periodontitis and gout. These studies, often conducted in animal models, aim to assess the peptide's impact on inflammatory responses and its potential to attenuate disease progression. The results from these investigations, coupled with its established safety profile in hundreds of autoimmune patients, underscore the broad therapeutic potential of P140Neuroimmunologie et thérapie peptidique (Pr Sylviane Muller ....
Peptide P140 is a 21-mer linear peptide with the amino acid sequence spanning positions 131-151 of the human spliceosomal U1-70K protein.P140is apeptidefrom the small nuclear ribonucleoprotein U1-70K, phosphorylated at the Ser140 position.P140binds to the HSPA8/HSC70 chaperone protein, ... A key feature of this therapeutic peptide is the phosphorylation at the serine residue at position 140, distinguishing it from its non-phosphorylated counterpart. This modification is crucial for its biological activity.作者：S Muller·2018·被引用次数：6—This matter is presented here, with thepeptide P140(Lupuzor™) as example. Two formulations of P140, differing in the excipients used (mannitol or trehalose), ...
The physicochemical properties of peptide P140 have also been investigated. Studies have examined its solubility in various media, including distilled water, phosphate-buffered saline (PBS), and cell culture media like RPMI 1640, as well as solutions containing excipients such as mannitol. Understanding these properties is vital for developing stable and effective pharmaceutical formulations.作者：N Schall·2015·被引用次数：27—Lupuzor/P140 peptidein patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. Ann Rheum Dis 2013; ... Different formulations of P140, utilizing excipients like mannitol or trehalose, have been explored to optimize drug delivery and stabilityThe Spliceosomal Phosphopeptide P140 Controls the Lupus ....
The ongoing research into peptide P140 highlights its significance as a novel therapeutic agent in the field of immunology. Its ability to reset the autoreactive immune system by selectively targeting pathogenic immune cells offers a new paradigm for treating autoimmune disorders.HSC70 blockade by the therapeutic peptide P140 affects ... While further clinical trials and research are essential to fully elucidate its potential and optimize treatment protocols, peptide P140 represents a beacon of hope for patients suffering from conditions currently managed with limited and often side-effect-prone therapies. The development of P140, or forigerimod, continues to be a key focus for researchers and pharmaceutical companies aiming to bring innovative immunomodulatory treatments to market.
Join the newsletter to receive news, updates, new products and freebies in your inbox.